CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Clinical Trials Arena
High ImpactOriginal article

Kolon TissueGene’s stock drops on Phase III knee osteoarthritis trial failure

Phase 3negativeNegative
AI Analysis

Summary

Kolon TissueGene's Phase III knee osteoarthritis trial failed, resulting in a nearly 30% stock price decline.

Clinical Trial Data

Phase

Phase III

Primary Endpoint

Not Met

Outcome Details

Phase III knee osteoarthritis trial failure

Importance:8/10
Sentiment:
-0.90
Phase 3 failureknee osteoarthritisstock dropclinical trial
Related Companies

Read the original article

Published by Clinical Trials Arena on July 21, 2026 3:15 PM

Read Original